CoChat

Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells

Open access

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Genomic instability is a hallmark of breast cancer, contributes to tumor heterogeneity, and influences chemotherapy resistance. Although Gap 2 and mitotic checkpoints are thought to prevent genomic instability, the role of these checkpoints in breast cancer is poorly understood. Here, we assess the Gap 2 and mitotic checkpoint functions of 24 breast cancer and immortalized mammary epithelial cell lines representing four of the six intrinsic molecular subtypes of breast cancer. We found that patterns of cell cycle checkpoint deregulation were associated with the intrinsic molecular subtype of breast cancer cell lines. Specifically, the luminal B and basal-like cell lines harbored two molecularly distinct Gap 2/mitosis checkpoint defects (impairment of the decatenation Gap 2 checkpoint and the spindle assembly checkpoint, respectively). All subtypes of breast cancer cell lines examined displayed aberrant DNA synthesis/Gap 2/mitosis progression and the basal-like and claudin-low cell lines exhibited increased percentages of chromatid cohesion defects. Furthermore, a decatenation Gap 2 checkpoint gene expression signature identified in the cell line panel correlated with clinical outcomes in breast cancer patients, suggesting that breast tumors may also harbor defects in decatenation Gap 2 checkpoint function. Taken together, these data imply that pharmacological targeting of signaling pathways driving these phenotypes may lead to the development of novel personalized treatment strategies for the latter two subtypes which currently lack targeted therapeutic options because of their triple negative breast cancer status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41523-017-0009-7

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Diagram of cell cycle regulation. Phases of the cell cycle are shown inside the blue circle in the center of the figure (G0, G1, S, G2, and mitosis which consists of several sub-phases: prophase (Pro), metaphase (Met), anaphase (Ana), and telophase (Tel)). The G0 Restriction Point is designated with a yellow dual headed arrow to illustrate the reversible nature of cell cycle entry and quiescence. As cells progress through the cycle, exogenous perturbations can activate checkpoints that arrest cells during phase transitions (checkpoints are designated by yellow lightning bolts). Several measures of cellular proliferation are shown in green and span the cell cycle phases in which these markers are present. Drugs that inhibit cell cycle progression are shown in orange with their targets and mechanisms of action designated in subsequent parentheses. Components of major regulatory pathways triggering each checkpoint are listed in dark blue font near the checkpoint in which they play a role. Precise control over the regulation of the cell cycle is a requirement for ensuring accurate DNA replication and cell division
Fig. 1 Diagram of cell cycle regulation. Phases of the cell cycle are shown inside the blue circle in the center of the figure (G0, G1, S, G2, and mitosis which consists of several sub-phases: prophase (Pro), metaphase (Met), anaphase (Ana), and telophase (Tel)). The G0 Restriction Point is designated with a yellow dual headed arrow to illustrate the reversible nature of cell cycle entry and quiescence. As cells progress through the cycle, exogenous perturbations can activate checkpoints that arrest cells during phase transitions (checkpoints are designated by yellow lightning bolts). Several measures of cellular proliferation are shown in green and span the cell cycle phases in which these markers are present. Drugs that inhibit cell cycle progression are shown in orange with their targets and mechanisms of action designated in subsequent parentheses. Components of major regulatory pathways triggering each checkpoint are listed in dark blue font near the checkpoint in which they play a role. Precise control over the regulation of the cell cycle is a requirement for ensuring accurate DNA replication and cell divisionCC BY · PubMed Central
Fig. 2 The decatenation G2 checkpoint response is impaired in luminal B (LumB) breast cancer cell lines. A panel of non-tumorigenic immortalized mammary epithelial cell lines (HMEC) and breast cancer cell lines were assessed for G2 and M checkpoint functions using a mitotic entry rate (MER) assay to monitor the rate of the G2/M transition in the presence of the topo II catalytic inhibitor ICRF-193 (decatenation G2 checkpoint) or the DNA-damaging topo II poison etoposide (DNA damage G2 checkpoint). a Example MERs of an HMEC (R-HMEC-E) cell line with effective decatenation and DNA damage G2 checkpoints and a LumB (MDA-MB-453) cell line with a defective decatenation G2 checkpoint. b and c The average percent inhibition of the MER of each cell line grouped according to intrinsic molecular subtype. Each point on the graph represents the average of 3 independent experiments for an individual cell line, and the bold lines represent the class average. d Example metaphases of LumB cell lines in the presence of DMSO exhibiting individualized chromosomes. Severely under-condensed and/or entangled chromosomes were observed in >88% of LumB cells upon treatment with 4 µM ICRF-193, suggesting that ICRF-193 is capable of inhibiting topoisomerase II in LumB cell lines. Percentages of entangled/under-condensed chromosomes are shown in the lower right hand corner of each ICRF-193 treated example. e HMECs activate p-Ser15 p53 after ICRF-193 or etoposide treatment (top panel). The HME-CC etoposide sample displayed aberrant mobility of ATM and reduced expression of p53 which could not be reproduced; therefore, this sample was omitted from the analysis. LumB cell lines exhibit reduced levels of p-Ser15 p53 in response to ICRF-193 (lower panel). Quantification of p53 activation is shown in the right panel. Data are representative of two independent experiments. *p-value < 0.05, **p-value that remains significant when controlling for FDR (5%), BL: basal-like, CL: claudin-low, Her2E: Her2-enriched
Fig. 2 The decatenation G2 checkpoint response is impaired in luminal B (LumB) breast cancer cell lines. A panel of non-tumorigenic immortalized mammary epithelial cell lines (HMEC) and breast cancer cell lines were assessed for G2 and M checkpoint functions using a mitotic entry rate (MER) assay to monitor the rate of the G2/M transition in the presence of the topo II catalytic inhibitor ICRF-193 (decatenation G2 checkpoint) or the DNA-damaging topo II poison etoposide (DNA damage G2 checkpoint). a Example MERs of an HMEC (R-HMEC-E) cell line with effective decatenation and DNA damage G2 checkpoints and a LumB (MDA-MB-453) cell line with a defective decatenation G2 checkpoint. b and c The average percent inhibition of the MER of each cell line grouped according to intrinsic molecular subtype. Each point on the graph represents the average of 3 independent experiments for an individual cell line, and the bold lines represent the class average. d Example metaphases of LumB cell lines in the presence of DMSO exhibiting individualized chromosomes. Severely under-condensed and/or entangled chromosomes were observed in >88% of LumB cells upon treatment with 4 µM ICRF-193, suggesting that ICRF-193 is capable of inhibiting topoisomerase II in LumB cell lines. Percentages of entangled/under-condensed chromosomes are shown in the lower right hand corner of each ICRF-193 treated example. e HMECs activate p-Ser15 p53 after ICRF-193 or etoposide treatment (top panel). The HME-CC etoposide sample displayed aberrant mobility of ATM and reduced expression of p53 which could not be reproduced; therefore, this sample was omitted from the analysis. LumB cell lines exhibit reduced levels of p-Ser15 p53 in response to ICRF-193 (lower panel). Quantification of p53 activation is shown in the right panel. Data are representative of two independent experiments. *p-value < 0.05, **p-value that remains significant when controlling for FDR (5%), BL: basal-like, CL: claudin-low, Her2E: Her2-enrichedCC BY · PubMed Central
Fig. 3 S/G2/M progression is aberrantly regulated in breast cancer cell lines of all classes. The average percentage of cells in S phase (a) or mitosis (b) and the MER (c) is shown for each cell line and grouped according to intrinsic molecular subtype. Each point represents the average of at least three independent experiments for an individual cell line, and the bold lines represent the class average. The Her2E class exhibited a lower S phase fraction, the BL class demonstrated a higher MI, and the BL, CL, and Her2E classes displayed lower MERs when compared to the HMEC class. d The population doubling level (PDL) over at least 11 weeks in cell culture was determined for each cell line, and the bold lines represent the class averages; both the LumB and Her2E classes exhibited low PDLs. *p-value < 0.05, **p-value that remains significant when controlling for false discovery rate (5%)
Fig. 3 S/G2/M progression is aberrantly regulated in breast cancer cell lines of all classes. The average percentage of cells in S phase (a) or mitosis (b) and the MER (c) is shown for each cell line and grouped according to intrinsic molecular subtype. Each point represents the average of at least three independent experiments for an individual cell line, and the bold lines represent the class average. The Her2E class exhibited a lower S phase fraction, the BL class demonstrated a higher MI, and the BL, CL, and Her2E classes displayed lower MERs when compared to the HMEC class. d The population doubling level (PDL) over at least 11 weeks in cell culture was determined for each cell line, and the bold lines represent the class averages; both the LumB and Her2E classes exhibited low PDLs. *p-value < 0.05, **p-value that remains significant when controlling for false discovery rate (5%)CC BY · PubMed Central
Fig. 4 The BL and CL cell line classes exhibit chromatid cohesion defects; the BL class also harbors a defective SAC. a Examples of cohesion defects observed in metaphase. The percentages of cells containing cohesion defects is shown for each cell line in the lower right corner of the cohesion defect picture. A “railroad” (RR) chromosome lacking a centromeric constriction point is designated with a black arrow in the SUM149 cell line to exemplify a mild cohesion defect. A severe cohesion defect is exemplified by the complete discohesion of the MDA-MB-436 metaphase. b Representative examples of the severity of cohesion defects observed during FISH analysis (upper panels). White arrows designate the centromere used for cohesion defect classification. Quantification of cohesion defects (lower panel) demonstrate that both the BL and CL classes exhibited variation in the distribution of chromatid cohesion defect severity when compared to the HMECs. Results shown were obtained from at least four different biological replicates for each subtype. c Flow cytometry examples reflecting SAC function in an HMEC line (MCF10A) and a BL breast cancer line (MDA-MB-468). Individual cell line averages obtained from at least three independent experiments are shown with bold lines representing the class average; the BL class exhibited a decrease in SAC function (right panel). *p-value < 0.05, **p-value that remains significant when controlling for false discovery rate (5%)
Fig. 4 The BL and CL cell line classes exhibit chromatid cohesion defects; the BL class also harbors a defective SAC. a Examples of cohesion defects observed in metaphase. The percentages of cells containing cohesion defects is shown for each cell line in the lower right corner of the cohesion defect picture. A “railroad” (RR) chromosome lacking a centromeric constriction point is designated with a black arrow in the SUM149 cell line to exemplify a mild cohesion defect. A severe cohesion defect is exemplified by the complete discohesion of the MDA-MB-436 metaphase. b Representative examples of the severity of cohesion defects observed during FISH analysis (upper panels). White arrows designate the centromere used for cohesion defect classification. Quantification of cohesion defects (lower panel) demonstrate that both the BL and CL classes exhibited variation in the distribution of chromatid cohesion defect severity when compared to the HMECs. Results shown were obtained from at least four different biological replicates for each subtype. c Flow cytometry examples reflecting SAC function in an HMEC line (MCF10A) and a BL breast cancer line (MDA-MB-468). Individual cell line averages obtained from at least three independent experiments are shown with bold lines representing the class average; the BL class exhibited a decrease in SAC function (right panel). *p-value < 0.05, **p-value that remains significant when controlling for false discovery rate (5%)CC BY · PubMed Central
Fig. 5 A decatenation G2 checkpoint gene expression signature correlates with clinical outcomes of breast cancer patients. a gene expression signature that positively correlated with decatenation G2 checkpoint function in the breast cancer cell line panel was identified and its relationship with clinical outcomes in the METABRIC study was assessed using a Cox proportional hazards model. A high expression of the decatenation G2 checkpoint signature was associated with better overall survival (OS) in all breast tumors (log rank p = 0.0176). b For the LumA subtype of breast tumors, high expression of the decatenation G2 checkpoint was associated with better OS outcomes (Log Rank p = 0.01741). c Median decatenation G2 checkpoint signature varies with intrinsic molecular subtype; LumA and LumB breast tumors exhibited the lowest median expression of the decatenation G2 checkpoint signature. HR: hazard ratio, OS: overall survival, CI: confidence intervals
Fig. 5 A decatenation G2 checkpoint gene expression signature correlates with clinical outcomes of breast cancer patients. a gene expression signature that positively correlated with decatenation G2 checkpoint function in the breast cancer cell line panel was identified and its relationship with clinical outcomes in the METABRIC study was assessed using a Cox proportional hazards model. A high expression of the decatenation G2 checkpoint signature was associated with better overall survival (OS) in all breast tumors (log rank p = 0.0176). b For the LumA subtype of breast tumors, high expression of the decatenation G2 checkpoint was associated with better OS outcomes (Log Rank p = 0.01741). c Median decatenation G2 checkpoint signature varies with intrinsic molecular subtype; LumA and LumB breast tumors exhibited the lowest median expression of the decatenation G2 checkpoint signature. HR: hazard ratio, OS: overall survival, CI: confidence intervalsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Research works printed but not linked: 1

  1. Andreassen, P. R., Skoufias, D. A. & Margolis, R. A. In Checkpoint Controls and Cancer: Activation and Regulation Protocols Vol. 2 Methods in Molecular Biology (ed Axel H. Schonthal) Ch. 15, 213-225 (Humana Press Inc., 2004).

Cited by

See all 76

Metadata

Authors
Bower, J. J., Vance, L. D., Psioda, M., Smith-Roe, S. L., Simpson, D. A., Ibrahim, J. G., Hoadley, K. A., Perou, C. M., & Kaufmann, W. K.
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
Bower, Jacquelyn J.
Venue
npj Breast Cancer
Published
2017-03-31
Volume
3
Issue
1
Pages
9-9
ISSN
2374-4677 (ISSN-L)
OpenAlex
W2603388361
Cited by
76
References
64
Citations by year
2026: 9 · 2025: 7 · 2024: 4 · 2023: 9 · 2022: 7 · 2021: 18 · 2020: 10 · 2019: 6 · 2018: 4 · 2017: 2
FWCI
3.21
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Breast Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UNC Libraries
Funders
  • Breast Cancer Research Foundation
  • National Institutes of Health (1f32ca134155-01, ES10126, CA58223, P50-CA58223-09A1)
  • National Cancer Institute (P50‐CA58223‐09A1, CA58223-09A1, P30-ES10126, CA-58223, F32 CA134155, CA 81343, P50 CA 58223, R01CA081343, T32CA106209, P50CA058223, P30CA016086)
  • National Institute of General Medical Sciences (R01GM070335)
  • National Institute of Environmental Health Sciences (P30ES010126)
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (P30-CA016086)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
breast cancer, cell cycle checkpoints, genomic instability, PAM50 molecular subtypes, spindle assembly checkpoint, luminal B, basal-like breast cancer, claudin-low breast cancer, triple-negative breast cancer, gene expression signatures, chemoresistance, tumor heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. https://app.cochat.ai/papers/10.1038/s41523-017-0009-7
The paper
Bower, J. J., Vance, L. D., Psioda, M., Smith-Roe, S. L., Simpson, D. A., Ibrahim, J. G., Hoadley, K. A., Perou, C. M., & Kaufmann, W. K. (2017). Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. npj Breast Cancer. https://doi.org/10.1038/s41523-017-0009-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.